Bli medlem
Bli medlem

Du är här


Biofrontera AG: Biofrontera starts with robust growth into the new year

Biofrontera AG / Biofrontera starts with robust growth into the new year.
Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is
solely responsible for the content of this announcement.
* Preliminary Q1 numbers indicate revenue increased by 59% to over EUR 1.0m
* German revenues up 44%
* Euro 247k from EU sales outside Germany

Leverkusen, 17 April 2015 - Biofrontera AG (AIM/FSE: B8F), the
biopharmaceutical company focusing on skin cancer, has recorded robust
revenue growth at the beginning of the new fiscal year. According to
preliminary numbers for the first quarter, total revenues were more than Euro
1.0m with Euro 247k generated outside Germany, mainly in Scandinavia and
Austria. In Germany revenues increased by 44% compared to the first quarter
of the previous year and amounted to Euro 783k.

Professor Hermann Lübbert, Chairman of the Executive Board, commented: "We are
very pleased with business development so far in the current year. We had
repeatedly emphasized that we would expect much larger revenues in 2015 and
the first quarter has fully confirmed our expectations. Growth in Germany is
even higher than anticipated. Although we do not extrapolate this growth and
maintain our guidance for the full year, this development provides us some
tail wind for the coming months."

Besides the expansion of the operational business Biofrontera's focus for this
fiscal year remains on two strategic goals: approval of our leading product
Ameluz®for the treatment of actinic keratosis in the USA as well as the
expansion of the approved indication to basal cell carcinoma in Europe. Both
goals should be met by 2016.

Final numbers will be announced with the Company's quarterly report on 29 May


Enquiries, please contact:

| Biofrontera AG +49 (0) 214 87 63 2 0 |
| |
|Prof. Hermann Lübbert, Chief Executive Officer |
|Thomas Schaffer, Chief Financial Officer |
| |
| IR Germany: Brainwell Asset Solutions +49 (0) 152 08931514 |
| |
|Jürgen Benker |
| Nomad and Broker: Shore Capital +44(0) 20 7408 4090 |
| |
|Bidhi Bhoma / Toby Gibbs |
| IR UK: Seton Services +44(0) 20 7603 6797 |
| |
|Toni Vallen |
| Financial PR: Gable Communications +44(0) 20 7193 7463 |
| |
|John Bick +44 (0)7872 061007 |

TheBiofrontera Group
(FSE/AIM: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising
in the development, sale and distribution of drugs and medical cosmetics for
the care and treatment of skin diseases. Biofrontera's most important product
, a prescription drug which is approved in Europe for the treatment of mild
and moderate actinic keratosis (superficial skin cancer) with photodynamic
therapy (light therapy). Biofrontera is the first German pharmaceutical
start-up company to obtain centralised approval for a drug it has developed
itself. The company also plans for Ameluz®to be approved for basal cell
carcinoma and is currently preparing for approval in other countries,
especially in the largest pharmaceutical market in the world, the United

The company also markets the Belixos®dermatological range of cosmetics.
Belixos®products contain combinations of active substances extracted from
plants, relieve itching and redness and are used for the regenerative care of
chronic skin conditions such as atopic dermatitis or psoriasis. At the
moment, Belixos®cream, gel and scalp tonic are available through Amazon.

The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lübbert, the
Chairman of the company's Management Board, and has its headquarters in
Leverkusen, Germany.

This communication expressly or implicitly contains certain forward-looking
statements concerning the business activities of Biofrontera AG. These
forward-looking statements reflect the opinion of Biofrontera at the time of
this communication and involve certain known and unknown risks. The actual
results achieved by Biofrontera may differ significantly from future results
or performances which are published in its forward-looking statements.
Biofrontera assumes no responsibility to update its forward-looking


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biofrontera AG via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.